Cognoptix: Simple Eye-Scan Test a Powerful Tool for Diagnosing Alzheimer’s Disease

Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer’s Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.

Read more »

Functional Neuromodulation CEO: Deep Brain Stimulation a Treatment for Alzheimer’s Disease

Charlottesville, VA-based Functional Neuromodulation is conducting an advanced trial of the application of Deep Brain Stimulation (DBS) therapy as a supplement for current Alzheimer’s Disease treatments. OneMedRadio’s Matt Margolis spoke with Dan O’Connell, co-founder and CEO of Functional Neuromodulation, about the science behind applying Deep Brain Stimulation to Alzheimer’s Disease, its current clinical trial, the lack of venture capital for Alzheimer’s research, and the regulatory obstacles that Functional Neuromodulation will face in the future.

Read more »

White Paper Explores the Amarantus Bioscience Alzheimer’s Disease Diagnostic

Amarantus Bioscience has posted a White Paper exploring the company’s LymPro Alzheimer’s Disease diagnostic, prepared by a member of the company’s Board of Advisors. The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.

Read more »

Cognoptix: Eye Scanning Test for Early Detection of Alzheimer’s Disease Represents Significant Market Opportunity

Cognoptix, presenting at the 6th Annaul OneMedForum, January 7-9 in San Francisco, is a privately held medical device company creating and developing a simple, innovative non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s Disease.

Read more »

Intellect Neurosciences Files New Patent Applications for Immunotherapy Methods in Treatment of Alzheimer’s Disease

Over the next 40 years, caring for individuals with Alzheimer’s will cost American society $20 trillion –including $15 trillion to Medicare and Medicaid.

Read more »

Protected: Functional Neuromodulation CEO: Deep Brain Stimulation the Next Step in Alzheimer’s Disease

There is no excerpt because this is a protected post.

Read more »

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

Anavex Life Sciences recently announced that its clinical trial application for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority.

Read more »

Neurotez Developing Hormone Replacement Therapy for Alzheimer’s

Could the same hormone that regulates your appetite keep you from developing Alzheimer’s?

Read more »

China Analyst Identifies 10 Pharma Stocks with Highest Growth Potential

China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.

Read more »

Annual Costs of Dementia Care Exceed GDP, New Report Says

If dementia care were a company, it would be the world’s largest in terms of annual revenue, surpassing even Wal-Mart.

Read more »